Nesiritide and Vo2 Max in Heart Failure Patients
Heart Failure
About this trial
This is an interventional treatment trial for Heart Failure
Eligibility Criteria
Inclusion Criteria: Aged 18-65 with NYHA Class II or III heart failure Referred to Strong Memorial Hospital for consideration of heart transplant Male or female and infertile or using effective contraception with negative pregnancy test Capable of IV access Able to perform a maximal bicycle test and tolerate mouthpiece and nose clip Fully understands and has signed Informed Consent Form before study begins Endogenous BNP level of at least 100 pg/mL Current smokers smoking < 3 cigarettes / day. Smoking is not permitted within the hospital, ergo subjects would not be permitted to smoke during study participation. Exclusion Criteria: NYHA Class i or IV heart failure Creatinine clearance < 30 ml/min, as determined within 2 weeks of the start of the study EF > 40% Evidence of primary lung disease Hypersensitivity to nesiritide or any of its' components Current smokers as defined by > 3 cigarettes / day Stroke within 3 months, myocardial infarction within 2 months, or any evidence of active myocardial ischemia Unwillingness ir inability to remain in the hospital overnight Clinical condition or laboratory abnormality which may increase risks associated with participation or interfere with result interpretation Any condition which would preclude heart transplantation.
Sites / Locations
- University of Rochester Medical Center
Arms of the Study
Arm 1
Experimental
Nesiritide infusion
Single arm study. 24-hour infusion of B-type Natriuretic Peptide at a dose of 0.01 mcg/kg/minute.